Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

This study tests a new treatment strategy for diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer. It starts with standard chemotherapy and uses interim PET scans and blood tests to decide whether to add an additional immunotherapy drug (glofitamab) to improve outcomes. **You may be eligible if...** - You are 18 or older and have been diagnosed with DLBCL or a related aggressive B-cell lymphoma - You have not previously been treated for DLBCL - You are considered eligible for full-dose chemotherapy by your oncologist - You are in good enough overall health to undergo intensive treatment **You may NOT be eligible if...** - You have received prior treatment for DLBCL - You have significant heart, liver, kidney, or lung problems - You have active infections including hepatitis B, hepatitis C, or HIV - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.